Last reviewed · How we verify
Resistant Potato Starch
Resistant Potato Starch is a Small molecule drug developed by VA Office of Research and Development. It is currently in Phase 2 development. Also known as: MSPrebiotic.
Resistant potato starch is a type of starch derived from potatoes, and it has been studied in clinical trials for various conditions, including breast cancer, with one such trial being the MICRO-VERZ study at the University of Vermont Medical Center. However, the exact mechanism of resistant potato starch is currently unknown.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Resistant Potato Starch |
|---|---|
| Also known as | MSPrebiotic |
| Sponsor | VA Office of Research and Development |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients (PHASE2)
- A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial (PHASE2)
- Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer (NA)
- Resistant Potato Starch to Alleviate GWI (PHASE2)
- Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy (NA)
- Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation (PHASE2)
- Study on the Effects of Resistant Potato Starch on Gut Bacteria in Healthy Adults (NA)
- Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Resistant Potato Starch CI brief — competitive landscape report
- Resistant Potato Starch updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI
Frequently asked questions about Resistant Potato Starch
What is Resistant Potato Starch?
Who makes Resistant Potato Starch?
Is Resistant Potato Starch also known as anything else?
What development phase is Resistant Potato Starch in?
Related
- Manufacturer: VA Office of Research and Development — full pipeline
- Also known as: MSPrebiotic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing